中国临床药理学杂志2025，Vol.41Issue(15)：2154-2159,6.DOI:10.13699/j.cnki.1001-6821.2025.15.010
抗高血压药物靶点与前列腺癌风险:一项双样本孟德尔随机化分析
Antihypertensive drug targets and prostate cancer risk:A two-sample Mendelian randomization study
摘要
Abstract
Objective To investigate the causal associations between genetically predicted expression of antihypertensive drug target genes and prostate cancer(PCa)risk to inform pharmacovigilance and guide therapeutic strategies in high-risk populations.Methods Genetic variants in cis-regulatory regions of antihypertensive drug target genes were selected as instrumental variables using genome-wide association study(GW AS)data for systolic blood pressure.Two-sample Mendelian randomization(MR)analysis,primarily using the inverse-variance weighted(IVW)method,was applied to assess the casual effects of target gene expression levels on PCa risk.Sensitivity analyses,including MR-PRESSO,were conducted to evaluate the robustness of the findings.Results IVW analysis revealed that elevated expression of ADRB2(OR=1.11,95％CI:1.04-1.17,P=1.07 × 10-3),AHR(OR=1.07,95％CI:1.03-1.10,P=7.08 × 10-4)and CALM3(OR=1.08,95％CI:1.05-1.11,P=2.18 ×10-8)were significantly associated with increased PCa risk,while higher expression of SLC16A1 exhibited a protective effect(OR=0.94,0.90-0.98,P=3.86 × 10-3).Sensitivity analyses yielded consistent results(P＞0.05).Conclusion This study identifies four antihypertensive drug targets with causal links to PC a risk,suggesting that medication optimization for high-risk populations should account for target-specific risks.关键词
抗高血压药物/前列腺癌/药物靶点/孟德尔随机化分析/基因表达Key words
antihypertensive medication/prostate cancer/drug targets/mendelian randomization/gene expression分类
医药卫生引用本文复制引用
陈琳,戎卓娜,谷延伦,刘鸿金,董秉琪,薛瑞芬,庞晓丛..抗高血压药物靶点与前列腺癌风险:一项双样本孟德尔随机化分析[J].中国临床药理学杂志,2025,41(15):2154-2159,6.基金项目
北京市自然科学基金-杰出青年科学基金资助项目(JQ24059) （JQ24059）
国家自然科学基金面上基金资助项目(82274015) （82274015）
北京市自然科学基金-昌平创新联合基金资助项目(L234038) （L234038）
国家自然科学基金国际(地区)合作与交流项目基金资助项目(12411530134) （地区）
